دورية أكاديمية
1841TiP Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
| العنوان: | 1841TiP Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP) |
|---|---|
| المؤلفون: | Morgans, A.K., Gschwend, J.E., Shore, N.D., Ross, A., Feng, F., Hope, T., Trandafir, L., Le Berre, M-A., Kuss, I., Joensuu, H., Fizazi, K. |
| المصدر: | In Annals of Oncology October 2023 34 Supplement 2:S997-S998 |
| قاعدة البيانات: | ScienceDirect |
| تدمد: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.09.2789 |